MELD Calculator vs myFibroScan

This update introduces the landmark MELD 3.0 formula, addressing long-standing gender disparities and improving mortality prediction. Key Features: MELD 3.0, Na-MELD, and Original MELD: View all three scores simultaneously on a single, high-density dashboard. Survival Probabilities: Real-time prediction of 30, 60, and 90-day survival based on the latest peer-reviewed hazard models. Clinical Accuracy: Implements the exact coefficients and bounds proposed in the 2021 MELD 3.0 research. Modern Aesthetic: A premium, minimalist design optimized for the iPhone, ensuring zero clutter and immediate visibility of critical metrics. Designed for Efficiency: Automated calculations and smart focus management allow for rapid data entry in fast-paced clinical environments. Scientific Reference: Based on the research: Kim WR, et al. "MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era." Gastroenterology (2021). Disclaimer: This tool is intended for educational and professional use by healthcare providers. It is not a substitute for clinical judgment.

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.